Advertisement

Reclassification of risk of malignancy with Percepta Genomic Sequencing Classifier following nondiagnostic bronchoscopy

Published:October 11, 2022DOI:https://doi.org/10.1016/j.rmed.2022.106990

      Highlights

      • Percepta GSC can reclassify malignancy risk after nondiagnostic bronchoscopy.
      • Data from four sites show that 42% of patients had a change in risk classification.
      • 35% of patients could potentially have avoided additional unnecessary procedures.

      Abstract

      Introduction

      Bronchoscopic sampling of pulmonary lesions suspicious for lung cancer is frequently nondiagnostic. A genomic sequencing classifier utilizing bronchial brushings obtained at the time of the bronchoscopy has been shown to provide an accurate reclassification of the risk of malignancy (ROM) based on pre-procedure risk. Our objectives for this study were to determine the frequency with which the classifier up- or down-classifies risk in regular clinical practice and to model the potential clinical utility of that reclassification.

      Methods

      This observational study retrospectively assessed data from four clinical sites that regularly use the genomic classifier in the bronchoscopic evaluation of indeterminate lesions. Demographics and pre-bronchoscopy ROM were recorded. The frequency of up- and down-classification was calculated. Modeling based on reclassification rates and the performance characteristics of the classifier was performed to demonstrate the potential clinical utility of the result.

      Results

      86 patients who underwent classifier testing following a nondiagnostic bronchoscopy were included. 45% of patients with high ROM prior to bronchoscopy were reclassified very high-risk. 38% of patients with intermediate ROM were up-or down-classified. 56% of patients with low ROM were reclassified to very low-risk. Overall, 42% of patients had a change in classification. 35% of the study cohort could potentially have avoided additional unnecessary procedures with subsequent guideline-adherent management.

      Conclusions

      The classifier can guide decision-making following a nondiagnostic bronchoscopy, reclassifying risk in a significant percentage of cases. Use of the classifier should allow more patients with early-stage cancer to proceed directly to curative therapy while helping more patients with benign disease avoid further unnecessary procedures.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Respiratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Silvestri G.A.
        • Bevill B.T.
        • Huang J.
        • et al.
        An evaluation of diagnostic yield from bronchoscopy: the impact of clinical/radiographic factors, procedure type, and Degree of suspicion for cancer.
        Chest. Jun. 2020; 157: 1656-1664https://doi.org/10.1016/j.chest.2019.12.024
        • Gould M.K.
        • Donington J.
        • Lynch W.R.
        • et al.
        Evaluation of individuals with pulmonary nodules: when is it lung cancer?: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines.
        Chest. 2013; 143: e93S-e120Shttps://doi.org/10.1378/chest.12-2351
        • Wang Memoli J.S.
        • Nietert P.J.
        • Silvestri G.A.
        Meta-analysis of guided bronchoscopy for the evaluation of the pulmonary nodule.
        Chest. Aug. 2012; 142: 385-393https://doi.org/10.1378/chest.11-1764
        • Silvestri G.A.
        Bronchoscopy for the solitary pulmonary nodule: friend or foe?.
        Chest. Aug 2012; 142: 276-277https://doi.org/10.1378/chest.12-0135
        • Tanner N.T.
        • Aggarwal J.
        • Gould M.K.
        • et al.
        Management of pulmonary nodules by community pulmonologists: a multicenter observational study.
        Chest. Dec. 2015; 148: 1405-1414https://doi.org/10.1378/chest.15-0630
        • Gasparini S.
        • Bonifazi M.
        • Wang K.P.
        Transbronchial needle aspirations vs. percutaneous needle aspirations.
        J. Thorac. Dis. Dec 2015; 7: S300-S303https://doi.org/10.3978/j.issn.2072-1439.2015.11.60
        • Chen A.C.
        • Pastis Jr., N.J.
        • Mahajan A.K.
        • et al.
        Robotic bronchoscopy for peripheral pulmonary lesions: a multicenter pilot and feasibility study (BENEFIT).
        Chest. Feb. 2021; 159: 845-852https://doi.org/10.1016/j.chest.2020.08.2047
        • Team A.S.
        Shared gene expression alterations in nasal and bronchial epithelium for lung cancer detection.
        J. Natl. Cancer Inst. Jul 1 2017; 109https://doi.org/10.1093/jnci/djw327
        • Silvestri G.A.
        • Vachani A.
        • Whitney D.
        • et al.
        A bronchial genomic classifier for the diagnostic evaluation of lung cancer.
        N. Engl. J. Med. 2015; 373: 243-251https://doi.org/10.1056/NEJMoa1504601
        • Choi Y.
        • Qu J.
        • Wu S.
        • et al.
        Improving lung cancer risk stratification leveraging whole transcriptome RNA sequencing and machine learning across multiple cohorts.
        BMC Med. Genom. Oct 22 2020; 13: 151https://doi.org/10.1186/s12920-020-00782-1
        • Gould M.K.
        • Altman D.E.
        • Creekmur B.
        • et al.
        Guidelines for the evaluation of pulmonary nodules detected incidentally or by screening: a survey of radiologist awareness, agreement, and adherence from the watch the spot trial.
        J Am Coll Radiol. Apr. 2021; 18: 545-553https://doi.org/10.1016/j.jacr.2020.10.003
        • Johnson M.K.
        • Wu S.
        • Pankratz D.G.
        • et al.
        Analytical validation of the Percepta genomic sequencing classifier; an RNA next generation sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules.
        BMC Cancer. Apr 13. 2021; 21: 400https://doi.org/10.1186/s12885-021-08130-x
        • Mazzone P.
        • Dotson T.
        • Wahidi M.M.
        • et al.
        Clinical validation and utility of Percepta GSC for the evaluation of lung cancer.
        PLoS One. 2022; 17e0268567https://doi.org/10.1371/journal.pone.0268567
        • Lee H.J.
        • Mazzone P.
        • Feller-Kopman D.
        • et al.
        Impact of the Percepta genomic classifier on clinical management decisions in a multicenter prospective study.
        Chest. Jan. 2021; 159: 401-412https://doi.org/10.1016/j.chest.2020.07.067
        • Mazzone P.J.
        • Sears C.R.
        • Arenberg D.A.
        • et al.
        Evaluating molecular biomarkers for the early detection of lung cancer: when is a biomarker ready for clinical use? An official American thoracic society policy statement.
        Am. J. Respir. Crit. Care Med. Oct 1 2017; 196: e15-e29https://doi.org/10.1164/rccm.201708-1678ST
        • Ferguson J.S.
        • Van Wert R.
        • Choi Y.
        • et al.
        Impact of a bronchial genomic classifier on clinical decision making in patients undergoing diagnostic evaluation for lung cancer.
        BMC Pulm. Med. May 17 2016; 16: 66https://doi.org/10.1186/s12890-016-0217-1
        • Gomez D.R.
        • Liao K.P.
        • Swisher S.G.
        • et al.
        Time to treatment as a quality metric in lung cancer: staging studies, time to treatment, and patient survival.
        Radiother. Oncol. May 2015; 115: 257-263https://doi.org/10.1016/j.radonc.2015.04.010
        • Kanarek N.F.
        • Hooker C.M.
        • Mathieu L.
        • et al.
        Survival after community diagnosis of early-stage non-small cell lung cancer.
        Am J Med. May. 2014; 127: 443-449https://doi.org/10.1016/j.amjmed.2013.12.023
        • Maiga A.W.
        • Deppen S.A.
        • Pinkerman R.
        • et al.
        Timeliness of care and lung cancer tumor-stage progression: how long can we wait?.
        Ann. Thorac. Surg. Dec 2017; 104: 1791-1797https://doi.org/10.1016/j.athoracsur.2017.06.051
        • Wegner R.E.
        • Ahmed N.
        • Hasan S.
        • Schumacher L.Y.
        • Van Deusen M.
        • Colonias A.
        SBRT for early stage lung cancer: outcomes from biopsy-proven and empirically treated lesions.
        Lung Cancer Manag. Mar. 2018; 7: LMT01https://doi.org/10.2217/lmt-2018-0006
        • Lokhandwala T.
        • Bittoni M.A.
        • Dann R.A.
        • et al.
        Costs of diagnostic assessment for lung cancer: a medicare claims analysis.
        Clin. Lung Cancer. Jan 2017; 18: e27-e34https://doi.org/10.1016/j.cllc.2016.07.006
        • Ost D.E.
        • Gould M.K.
        Decision making in patients with pulmonary nodules.
        Am J Respir Crit Care Med. Feb 15. 2012; 185: 363-372https://doi.org/10.1164/rccm.201104-0679CI